Dr. Clay Siegall and his company Seattle Genetics are leading the battle to develop and distribute as widely as possible effective treatments for cancer. It’s a battle in which Dr. Clay Siegall has been involved for more than 20 years. His work to find viable cancer treatments has led him to hold positions with the National Institutes of Health, Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and many of the other top companies involved in cancer research. The experience he gained through working with these companies has been important to his success.
Since Dr. Siegall co-founded the Bothell, Washington cancer research company Seattle Genetics in 1998, the company has quickly become an industry leader when it comes to developing effective cancer treatments. In addition to having a fertile development pipeline with a wide array of promising cancer treatments, Dr. Siegall and Seattle Genetics received FDA approval in 2011 for their antibody-drug conjugate ADCETRIS. Through licensing agreements with a number of major pharmaceutical companies, ADCETRIS is now used in over 60 countries around the world to treat cancer patients.
Dr. Clay Siegall attended the University of Maryland where he earned a bachelor’s degree in zoology. He then got a Ph.D. in genetics from George Washington University. Since then he’s worked diligently to help come up with innovative, new ways to treat cancer. His papers on the topic have been published widely and he has also patented more than a dozen inventions. But he’s best known for his work with Seattle Genetics. That work led to him being voted Entrepreneur of the Year by Ernst & Young in 2012.
In addition to his groundbreaking work with Seattle Genetics, Dr. Siegall is also on the board of the Fred Hutchinson Cancer Research Center, Alder Biopharmaceuticals, Mirna Therapeutics and Ultragenyx Pharmaceutical. In 2013 his alma mater, the University of Maryland, named him their Alumnus of the Year for Computer, Math and Natural Sciences. One of the most important roles Dr. Siegall plays with Seattle Genetics is chief fundraiser. Since co-founding the company, he has raised over $1.2 billion to invest in their work.